Trv Gp V LLC Buys Shares of 950,800 Maze Therapeutics, Inc. $MAZE

Key Points

• Trv Gp V LLC acquired 950,800 shares of Maze Therapeutics in the second quarter, giving it approximately 1.72% of the company and making MAZE its third-largest portfolio holding at 5.7%.
• Institutional interest increased as TRV GP IV, BlackRock, Deutsche Bank, Alphabet and Mitsubishi UFJ also initiated positions. Analysts remain broadly positive, with an average “Buy” rating and a $66 target price, despite some “Sell” ratings.
• Maze shares opened at $29.13 after rising 4.2%; the company met quarterly EPS estimates at a loss of $0.76 per share. Insiders have sold 140,674 shares worth about $3.9 million over the past 90 days.

Trv Gp V LLC bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 950,800 shares of the company's stock, valued at approximately $28,371,872,000. Maze Therapeutics makes up approximately 5.7% of Trv Gp V LLC's investment portfolio, making the stock its 3rd largest position. Trv Gp V LLC owned approximately 1.72% of Maze Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of MAZE. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics during the second quarter valued at $133,502,907,000. BlackRock Inc. purchased a new stake in Maze Therapeutics in the 2nd quarter worth about $104,525,000. Deutsche Bank AG acquired a new stake in Maze Therapeutics during the 2nd quarter worth about $1,044,000. Alphabet Inc. acquired a new stake in Maze Therapeutics during the 2nd quarter worth about $41,435,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics during the 2nd quarter valued at about $48,000.

Get Maze Therapeutics SMS alerts:

Sign Up

Wall Street Analysts Forecast Growth

MAZE has been the subject of several research reports. Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, BTIG Research reiterated a "buy" rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $66.00.

Insider Transactions at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the firm's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider owned 26,250 shares in the company, valued at approximately $717,675. This trade represents a 22.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the sale, the chief executive officer directly owned 23,337 shares of the company's stock, valued at approximately $699,643.26. The trade was a 59.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 140,674 shares of company stock worth $3,904,707 in the last 90 days. 5.30% of the stock is owned by insiders.

Maze Therapeutics Trading Up 4.2%

NASDAQ:MAZE opened at $29.13 on Wednesday. The company has a market capitalization of $1.62 billion, a P/E ratio of -11.56 and a beta of 2.22. The stock's 50 day moving average price is $27.98 and its 200 day moving average price is $32.73. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics, Inc. has a 52 week low of $12.81 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.76). On average, research analysts forecast that Maze Therapeutics, Inc. will post -2.71 EPS for the current fiscal year.

Maze Therapeutics Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source